NCT00984971View on ClinicalTrials.gov

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

July 31, 2010

Conditions
HIV PreventionHIV Infections
Interventions
DRUG

Tenofovir

Topical gel applied rectally

DRUG

HEC Placebo

Placebo gel applied rectally

DRUG

Open label tenofovir tablet

All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)

Trial Locations (2)

15213

University of Pittsburgh Clinical Research Unit, Pittsburgh

90024

UCLA Center for HIV Prevention Research, Los Angeles

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Microbicide Trials Network

NETWORK

lead

CONRAD

OTHER